I Christou1, W S Burgin, A V Alexandrov, J C Grotta. 1. Center for Noninvasive Brain Perfusion Studies, Stroke Treatment Team, University of Texas-Houston Medical School, Houston, Texas, USA. avalexandrov@worldnet.att.net
Abstract
BACKGROUND: Intravenous tissue plasminogen activator (TPA) is an approved therapy for acute ischaemic stroke in the United States. We aimed to noninvasively monitor the therapy to determine arterial recanalisation and persisting vascular abnormalities. METHODS: We prospectively studied consecutive patients with symptoms of ischaemic stroke who received intravenous TPA and were monitored by 2 MHz transcranial Doppler (TCD) to determine occlusion and recanalisation (TIMI grades equivalent). For outcome assessment we used the National Institutes of Health Stroke Scale (NIHSS) score. RESULTS: Sixty patients were studied (age 71+/-15 years, pre-TPA NIHSS 18+/-6.1, TPA bolus at 141+/-68 min after stroke onset). The internal carotid artery (ICA) was occluded in 25%, middle cerebral artery (MCA) in 80%; combined (ICA+MCA) occlusion was found in 19%; and basilar artery (BA) was occluded in 7%. Also, 2% had normal TCD and 8% of patients had no temporal windows. Complete recanalisation on TCD of all insonated arteries was found in 19 patients (32%) at 44+/-22 min after a TPA bolus. However, 67% of MCA, 25% of BA, and all ICA occlusions did not completely recanalise (TIMI grades 0-2). If flow impairment persisted for more than two hours after a TPA bolus, these patients continued to have significant neurological deficits at 24 hours (15.0+/-8.2 vs 6.3+/-7.3 NIHSS points, p<0.001 in non-parametric statistics). High-grade residual stenoses with microembolic signals were seen on TCD in the MCA and BA (n=3) suggesting continuing clot dissolution. In patients without complete recanalisation (n=36, or 60%), TCD identified lesions potentially amenable to further interventions. CONCLUSIONS: Persisting arterial occlusion after intravenous TPA therapy leads to poor short-term outcome. Noninvasive monitoring of TPA therapy with TCD can identify these high-risk patients for combined interventions such as intra-arterial thrombolysis, mechanical clot disruption, stenting or anticoagulation.
BACKGROUND: Intravenous tissue plasminogen activator (TPA) is an approved therapy for acute ischaemic stroke in the United States. We aimed to noninvasively monitor the therapy to determine arterial recanalisation and persisting vascular abnormalities. METHODS: We prospectively studied consecutive patients with symptoms of ischaemic stroke who received intravenous TPA and were monitored by 2 MHz transcranial Doppler (TCD) to determine occlusion and recanalisation (TIMI grades equivalent). For outcome assessment we used the National Institutes of Health Stroke Scale (NIHSS) score. RESULTS: Sixty patients were studied (age 71+/-15 years, pre-TPA NIHSS 18+/-6.1, TPA bolus at 141+/-68 min after stroke onset). The internal carotid artery (ICA) was occluded in 25%, middle cerebral artery (MCA) in 80%; combined (ICA+MCA) occlusion was found in 19%; and basilar artery (BA) was occluded in 7%. Also, 2% had normal TCD and 8% of patients had no temporal windows. Complete recanalisation on TCD of all insonated arteries was found in 19 patients (32%) at 44+/-22 min after a TPA bolus. However, 67% of MCA, 25% of BA, and all ICA occlusions did not completely recanalise (TIMI grades 0-2). If flow impairment persisted for more than two hours after a TPA bolus, these patients continued to have significant neurological deficits at 24 hours (15.0+/-8.2 vs 6.3+/-7.3 NIHSS points, p<0.001 in non-parametric statistics). High-grade residual stenoses with microembolic signals were seen on TCD in the MCA and BA (n=3) suggesting continuing clot dissolution. In patients without complete recanalisation (n=36, or 60%), TCD identified lesions potentially amenable to further interventions. CONCLUSIONS: Persisting arterial occlusion after intravenous TPA therapy leads to poor short-term outcome. Noninvasive monitoring of TPA therapy with TCD can identify these high-risk patients for combined interventions such as intra-arterial thrombolysis, mechanical clot disruption, stenting or anticoagulation.
Authors: David Fussell; H Christian Schumacher; Philip M Meyers; Randall T Higashida Journal: Curr Neurol Neurosci Rep Date: 2007-01 Impact factor: 5.081
Authors: Christopher T Richards; Ryan Huebinger; Katie L Tataris; Joseph M Weber; Laura Eggers; Eddie Markul; Leslee Stein-Spencer; Kenneth S Pearlman; Jane L Holl; Shyam Prabhakaran Journal: Prehosp Emerg Care Date: 2018-01-03 Impact factor: 3.077
Authors: Dagmar Krajíčková; Antonín Krajina; Roman Herzig; Miroslav Lojík; Vendelín Chovanec; Jan Raupach; Eva Vítková; Jan Waishaupt; Oldřich Vyšata; Martin Vališ Journal: Diagn Interv Radiol Date: 2017 Nov-Dec Impact factor: 2.630
Authors: Dong Joon Kim; Dong Ik Kim; Seo Hyun Kim; Kyung Yeol Lee; Ji Hoe Heo; Sang Won Han Journal: Neuroradiology Date: 2005-06-28 Impact factor: 2.804
Authors: Joon K Song; Edwin D Cacayorin; Morgan S Campbell; Stanley Fisher; Marc D Malkoff; Andrei V Alexandrov; James C Grotta Journal: AJNR Am J Neuroradiol Date: 2002-09 Impact factor: 3.825
Authors: Raimund Pechlaner; Michael Knoflach; Benjamin Matosevic; Michael Ruecker; Christoph Schmidauer; Stefan Kiechl; Johann Willeit Journal: PLoS One Date: 2013-01-28 Impact factor: 3.240